BSX · Q2 2025 Earnings
CautiousBoston Scientific
Reported July 23, 2025
30-second summary
30-second take: Boston Scientific delivered 22.8% reported revenue growth to $5.06B (beating the 17.5–19.5% Q2 guide) with adjusted EPS of $0.75 (above the $0.71–$0.73 guide) and raised the FY2025 outlook to 18–19% reported / 14–15% organic growth with adjusted EPS of $2.95–$2.99. Cardiovascular grew 26.8% and Cardiology 29.3%, carrying the quarter, while Endoscopy (+9.1%) and Neuromodulation (+7.2%) lagged materially. The more important signal sits in Q&A: management spent meaningful airtime qualifying the ASC migration story — slower than implied, regulatory-constrained to ~40% of the US market near-term, and structurally dilutive to Watchman concomitant attach rates because ASC-bound patients are the wrong acuity profile.
Headline numbers
EPS
Q2 FY2025
$0.75
Revenue
Q2 FY2025
$5.06B
+22.8% YoY
Gross margin
Q2 FY2025
67.7%
Operating margin
Q2 FY2025
16.2%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $5.06B | +22.8% |
| EPS | $0.75 | — |
| Gross margin | 67.7% | — |
| Operating margin | 16.2% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| MedSurg | $1.716B | +15.7% |
| Cardiovascular | $3.345B | +26.8% |
| Endoscopy | $0.737B | +9.1% |
| Urology | $0.676B | +28.9% |
| Neuromodulation | $0.303B | +7.2% |
| Cardiology | $2.647B | +29.3% |
| Peripheral Interventions | $0.698B | +18.3% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| United States | $3.224B | +30.7% |
| EMEA | $0.878B | +6.8% |
| APAC | $0.79B | +18.0% |
| LACA | $0.169B | +4.0% |
| Emerging Markets | $0.758B | +11.6% |
| Organic Revenue Growth | 17.4% | — |
| Operational Revenue Growth | 21.6% | — |
| Adjusted EPS | $0.75 | — |
| Gross Margin | 67.7% | — |
| Operating Margin | 16.2% | — |
Management tone
The dominant shift on this call is that management is now openly qualifying the ASC migration story they previously framed as a clean tailwind. Three quarters ago the ASC rule was discussed in broad-strokes growth terms; on this call, CEO commentary repeatedly pulled it back to "much more gradual" and "market-dependent." The verbatim anchor: "the other 60% of the market, it's a much more gradual ability to build out into the ASC." This isn't a thesis break, but it is a measurable downgrade in the slope of an investor talking point — the kind of recalibration that usually shows up in sell-side models a quarter later.
A related, more uncomfortable concession surfaced on the concomitant Watchman attach rate. Management acknowledged that ASC-bound AFib patients are structurally the wrong patients for Watchman: "those are the opposite of the patients, right, who are candidates for the concomitant procedure… The younger you are, the less comorbidities you have, the lower your risk for stroke." The implication is that as procedure volume migrates to ASC, the mix shift mechanically dilutes Watchman attach economics. Management deflected to FARAPULSE ecosystem differentiation — "We really see ourselves as having really important differentiated advantages based on the entire FARAPULSE ecosystem" — which is a product-defensibility answer to what is fundamentally a patient-mix question.
Third, the regulatory environment got framed more honestly than is typical. Management volunteered that CON-state restrictions cap the addressable near-term ASC opportunity at roughly 40% of US AFib volume. Pairing that with a "this is a proposed rule. Assuming that it gets approved" caveat is unusually defensive language for a medtech CEO discussing a favorable rule change. Compared to peer commentary on similar regulatory shifts, this is preemptive damage control rather than victory-lap framing.
Finally, the OPEX trajectory turned more conservative. CFO confirmed a deliberate Q2 OPEX hold tied to the April tariff updates and the ACURATE discontinuation, with $100M of tariff impact landing predominantly in H2. Management is still targeting 75–100bps of operating margin expansion for the year (adjusted basis), but the path now involves a deliberate Q3 R&D step-up against tariff headwinds — a tighter operating envelope than the H1 print implies.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
David Roman · Goldman Sachs
Deep dive on EP portfolio evolution: current adoption patterns, indication expansion strategy, mapping investments, upcoming product launches (TheraPoint, ICE catheter), and path to capturing totality of EP market across procedures and disposables.
Strategy targets category leadership across full EP toolkit. FaroPulse already seeing significant use in persistent AFib beyond PVI. Second-gen PFA catheter ahead of most competitors' first-gen. FaraPoint approval expected H2 2024. FaraFlex in first human use. Geographic expansion underway in Japan (market leader position) and early-stage China. Commitment to continued iteration and ecosystem expansion.
David Roman · Goldman Sachs
P&L follow-up: Q1 showed slower OPEX start, Q2 saw deliberate OPEX holdback to offset Accuratus charge. With tariff headwinds ahead, are we approaching a point where operating leverage emerges or is OPEX management more deliberate?
Q2 OPEX holdback was tactical response to tariff updates and Accuratus discontinuation announcement. Second half expects $100M tariff impact predominantly in back half. Planned reinvestment into R&D and commercial activities for differentiated growth. Company targeting 75-100 basis points of op margin expansion for year while reinvesting.
Michael Pollark · Wolf Research
Medicare LAA physician fee proposed down 16% year-over-year with medical societies opposing. Given strong Watchman momentum and innovation pipeline (Form factor, concomitant, CHAMPION), how material is this reimbursement challenge and does management agree with Medicare's mapping?
Management believes payment should reflect procedure complexity and physician decision-making involved. Committed to supporting medical societies' advocacy efforts. Maintains confidence that physicians will choose clinically appropriate treatment and won't be prevented from treating stroke prevention cases despite proposed rate cuts.
Danielle Antelfi · EBS
Capacity constraints for concurrent Watchman/FaraPulse procedures and TheraPulse penetration into lower-volume centers. Are capacity issues emerging and is TheraPulse reaching previously low-volume centers to democratize ablation?
No capacity issues currently observed despite procedure complexity. Strong hospital profitability driving investment in additional labs. Healthy backlogs persist across centers. ASC ruling potential (effective 2026) could address capacity by enabling PVI/posterior wall procedures to migrate to ASC in ~40% of US AFib volume (20 states without certificate of need). TheraPulse rollout expanding from highest-volume centers to smaller centers as commercial and clinical footprint scales.
What to watch into next quarter
Watchman concomitant attach rate trajectory — management conceded ASC patients are structurally the wrong acuity for concomitant Watchman. Track whether Q3 disclosure quantifies attach rates by setting (hospital vs ASC) or remains qualitative; a refusal to disclose would itself be a signal.
H2 operating margin against the $100M tariff drag — FY target of 75–100bps expansion requires Q3/Q4 op margin to absorb tariff impact while accommodating the flagged R&D step-up. Watch whether the FY adjusted EPS range of $2.95–$2.99 holds or narrows on the Q3 print.
EMEA and LACA re-acceleration — at +6.8% and +4.0% respectively versus 30.7% in the US, the geographic spread is unusually wide for BSX. A second consecutive single-digit EMEA quarter would suggest more than mix noise.
Neuromodulation inflection — +7.2% growth in a quarter where the company average was 22.8% puts Neuromod as the persistent underperformer. Watch for management commentary on whether this is product-cycle timing or share loss.
FARAPOINT approval and FARAFLEX trial readouts — the EP portfolio roadmap leans on these two assets to extend the FARAPULSE moat into second-gen territory before competitor first-gen launches.
Proposed ASC rule finalization — management's hedged "assuming that it gets approved" language flags this as a real, not procedural, risk. A delay or modification to the rule would re-base Street ASC-driven growth assumptions for 2026.
Sources
- Boston Scientific Q2 2025 Earnings Release (SEC EDGAR): https://www.sec.gov/Archives/edgar/data/885725/000088572525000039/q22025earningsrelease.htm
- Q2 2025 earnings call Q&A (analyst exchanges with Goldman Sachs, Wolfe Research, Piper Sandler)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.